Rituximab: modes of action, remaining dispute and future perspective | Future Oncology
Rituximab (Rituxan) | American Journal of Neuroradiology
Rituximab for the treatment of multiple sclerosis: a review | SpringerLink
Lessons for rituximab therapy in patients with rheumatoid arthritis - The Lancet Rheumatology
Rituximab mode of action: apoptosis and ADCC. Rituximab mediated... | Download Scientific Diagram
PV | RITUXAN® (rituximab) Proposed Mechanism of Action (MoA)
Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial - The Lancet
B-Cell Targeted Therapies: Clinical Trials Update
Cells | Free Full-Text | Biologic Drugs for Rheumatoid Arthritis in the Context of Biosimilars, Genetics, Epigenetics and COVID-19 Treatment
B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience | Annals of the Rheumatic Diseases
Internet Scientific Publications
Mechanism of action of rituximab. Rituximab is a monoclonal antibody... | Download Scientific Diagram
A review of the current use of rituximab in autoimmune diseases - ScienceDirect
Biological Therapy for Rheumatoid Arthritis - ppt download
Role of biological agents in treatment of rheumatoid arthritis - ScienceDirect
RA | RITUXAN® (rituximab) Proposed Mechanism of Action (MoA) in Rheumatoid Arthritis
Rituximab - Wikipedia
The value of rituximab treatment in primary Sjögren's syndrome - ScienceDirect
Frontiers | Rituximab Therapy for Primary Sjögren's Syndrome
Drug Insight: the mechanism of action of rituximab in autoimmune disease—the immune complex decoy hypothesis | Nature Reviews Rheumatology
Empowering Targeted Therapy: Lessons from Rituximab | Science's STKE
Anti‐CD20 Antibody Rituximab in the Treatment of Rheumatoid Arthritis - Korhonen - 2010 - Basic & Clinical Pharmacology & Toxicology - Wiley Online Library
